MedPath
FDA Approval

Deferoxamine mesylate

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Apotex Corp.
DUNS: 845263701
Effective Date
December 1, 2023
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Deferoxamine(2 g in 1 1)

Products2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Deferoxamine mesylate

Product Details

NDC Product Code
60505-6237
Application Number
ANDA207384
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS
Effective Date
December 1, 2023
Code: V9TKO7EO6KClass: ACTIBQuantity: 2 g in 1 1

Deferoxamine mesylate

Product Details

NDC Product Code
60505-6236
Application Number
ANDA207384
Marketing Category
ANDA (C73584)
Route of Administration
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
Effective Date
December 1, 2023
Code: V9TKO7EO6KClass: ACTIBQuantity: 500 mg in 1 1
© Copyright 2025. All Rights Reserved by MedPath